Monograph is a software company that provides a modern, all-in-one platform for architecture firms. The platform is designed to streamline project management, time tracking, and financial reporting, helping architects manage their projects more efficiently and profitably.

Monograph Capital

Monograph.io

Monograph was founded to invest in life sciences companies that seek to create new or improved therapeutics, diagnostics and related technology-enabled business services which enhance healthcare outcomes.  With primary offices in London, San Francisco and Dallas-Fort Worth, Monograph bridges opportunities across North America, the United Kingdom and Europe, bringing deep experience, relationships, and capabilities to help these companies scale.  

The Monograph team combines decades of experience in biomedical research and clinical medicine with over 55 years of investing experience in the healthcare industry cumulatively across the Monograph Partners.  This experience allows Monograph to actively contribute to the growth of nascent organizations into promising biotechnology and related life sciences businesses.  Monograph routinely sees opportunities it believes could contribute to transformational healthcare outcomes.

MiroBio

Monograph is on a mission to connect the best biotech executives - case in point with Maxion bringing Arndt Schottelius, MD PhD as their CEO.

Monograph is excited to join a stellar investor syndicate and management team to support Sudo as they progress their pipeline of TYK2 inhibitors into the clinic.

Travis Murdoch, MD is a Partner and co-Founder at Monograph Capital and CEO of portfolio company Human Immunology Biosciences (“Hi-Bio”), a precision immunology company. 

Prior to Monograph, Travis was a life sciences investor with Softbank Vision Fund, where he oversaw investments in Relay Therapeutics (NASDAQ: RLAY), Vividion Therapeutics (Acqby: BAYRY), Seer (NASDAQ: SEER), VIR (NASDAQ: VIR), Zymergen(NASDAQ: ZY), ElevateBio, Encoded Therapeutics, Insitro, Karius, and Collective Health. He was previously a Principal at Third Rock Ventures, and a consultant at McKinsey & Company.

Travis is a gastroenterologist who worked with Northern communities in Canada. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.

Join Travis for his 10:00 AM panel, “Opportunities in Venture Capital at every Stage” on November 7th at the Texas LP Summit in Dallas.

To learn more about Monograph Capital, click here: https://lnkd.in/eMqnugh2

Secure Your Spot for Dallas, here: https://lnkd.in/ekCe599X

#PortfolioSummits #Dallas #Investor

Our portfolio company, AviadoBio advances to the clinic with the initiation of the ASPIRE trial for frontotemporal dementia. We are very pleased to be supporting them as they address this important disease with a therapy designed to halt progression of neurodegeneration.

Monograph is excited to support Urogen in their mission to transform the way urothelial and specialty cancers are treated. This represents our first PIPE investment in our current fund.

We are excited to partner with UroGen Pharma; the latest addition to the Monograph portfolio.

Monograph Capital is pleased to announce a company we’ve been working on for the past 18 months – Ascend Gene & Cell Therapies brings together experienced teams and technologies to create a new offering for gene and cell therapy manufacturing. 
 
Our team have been deeply involved in the build; with Fred Cohen as Chairman, Tim Funnell as Interim CEO to launch and Freddie Dear leading M&A as VP of Corporate Development. 
 
We are pleased to now work alongside a strong syndicate as the company emerges with a total of $130M raised.
 
Meet the rest of the Ascend team here 👉 https://lnkd.in/epMph6Es

#cellandgenetherapy #genetherapy #therapeutics

BIO:MONOGRAPH

Monograph.io

locale

market

industry

website

crunchbase

linkedin

peer of

invested in

competitor of

Metrics